Medicines labeled for the same conditions
Alternatives to ponatinib
37 other medicines are given the same way (oral) and in the same FDA class as ponatinib or labeled mainly for the same use (leukemia, lymphoma and myeloma); 10 are in its class, kinase inhibitors: dasatinib, imatinib, nilotinib, bosutinib and 6 more; the others include 3 alkylating drugs, 3 nucleoside metabolic inhibitors and 2 thalidomide analogs (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $0.624 per imatinib mesylate 100 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as ponatinib?
The first 24 of the 37, the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Ponatinibkinase inhibitor | this medicine | none listed | n/a | Yes | No current entry |
| Dasatinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | 14 labelers | $26.46 per tablet 100 mg tablet | No | No current entry |
| Imatinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | 20 labelers | $0.624 per tablet 100 mg tablet | No | No current entry |
| Nilotinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | 6 labelers | n/a | Yes | No current entry |
| Bosutinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | 3 labelers | n/a | No | No current entry |
| Ibrutinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Acalabrutinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Pirtobrutinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Quizartinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Zanubrutinibkinase inhibitor · same class | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Midostaurinkinase inhibitor · same class | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Lenalidomidethalidomide analog | Leukemia, lymphoma and myeloma | 18 labelers | n/a | Yes | No current entry |
| Pomalidomidethalidomide analog | Leukemia, lymphoma and myeloma | 11 labelers | n/a | Yes | No current entry |
| Arsenic trioxide | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | A presentation being discontinued |
| Hydroxyureaantimetabolite | Leukemia, lymphoma and myeloma | 10 labelers | $0.184 per capsule 500 mg capsule | No | No current entry |
| Cyclophosphamidealkylating drug | Leukemia, lymphoma and myeloma | 4 labelers | $1.67 per capsule 50 mg capsule | No | No current entry |
| Bexaroteneretinoid | Leukemia, lymphoma and myeloma | 7 labelers | n/a | Yes | No current entry |
| Mercaptopurinenucleoside metabolic inhibitor | Leukemia, lymphoma and myeloma | 2 labelers | $1.07 per tablet 50 mg tablet | No | No current entry |
| Selinexornuclear export inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Sonrotoclax | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Thalidomide | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Asciminib | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Ixazomibproteasome inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Revumenibmenin inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Venetoclaxbcl-2 inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Ponatinib: the full record
- label, generics, price, shortages, recalls